In January 2017, the AMA and 16 other healthcare organizations (Table), which represent physicians, medical groups, hospitals, pharmacists, and patients, announced that they had formed a coalition to help streamline the prior authorization process for medical tests, procedures, devices, and drugs to reduce administrative waste and save time.
The full impact of the 2016 presidential election is still unknown, but there is a key issue to keep on your radar as we enter 2017. Value-based healthcare is a reality, and its far-reaching impact needs to be front and center on your radar for 2017.
ACR Applauds 21st Century Cures Act, But Urges Congress to Dedicate Funds for Arthritis Research Program
Former President Barack Obama signed the 21st Century Cures Act into law.1 This legislation will allocate approximately $4.8 billion in crucial funding for medical research at the National Institutes of Health (NIH) that will span the next 10 years, including $1.4 billion for the Precision Medicine Initiative, $1.8 billion for the Brain Research Through Advancing Innovative Neurotechnologies Initiative, and $1.8 billion for the Cancer Moonshot initiative.2,3
The following clinical trials represent a selection of key studies that are currently recruiting patients with psoriatic arthritis for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
Institute for Clinical and Economic Review Releases Draft Report on Therapies for Rheumatoid Arthritis
On March 24, 2017, this report will be the topic of a free, public meeting held by the New England Comparative Effectiveness Public Advisory Council, a nationally recognized community forum and core program of Institute for Clinical and Economic Review, in Boston, MA. During this meeting, recommendations that can be translated to policy and practice in the field of rheumatology will be deliberated by an expert policy roundtable, and the New England Comparative Effectiveness Public Advisory Council will vote on important questions brought up in the Draft Evidence Report.
In the coming year, NORM and Rheumatology Practice Management will strive to provide practice managers with the information and resources they need to deliver quality patient care.
According to the ACR, a practical benefit of the guidance is that in situations where a biosimilar is not considered interchangeable, a pharmacist must ask the prescribing physician for a new prescription before switching a patient to or from a reference biologic.
The National Organization of Rheumatology Managers (NORM) hosted a Centers for Medicare & Medicaid (CMS) webinar on the Quality Payment Program—which is based on the Medicare Access and CHIP Reauthorization Act (MACRA)—for NORM members.
Results 1 - 8 of 8